Organicell Regenerative Medicine, Inc. (BPSR) Stock Analysis

Organicell Regenerative Medicine, Inc. (BPSR) Healthcare & Pipeline Overview

Organicell Regenerative Medicine, Inc. is a Miami-based biotechnology firm specializing in cellular and tissue products for therapeutic applications within the U.S. Since its 2011 founding, the company focuses on regenerative medicine, notably exploring Zofin's potential for heart failure treatment through a partnership with Regenerative Care Network, positioning it in a high-growth healthcare segment.

What Is the Investment Thesis for BPSR?

Organicell Regenerative Medicine, Inc. presents an investment profile centered on its specialization in biologically derived cellular and tissue products, particularly its lead candidate, Zofin, for heart failure. The company's high gross margin of 81.6% suggests strong product economics or efficient production processes for its specialized offerings. The strategic partnership with Regenerative Care Network for Zofin's therapeutic exploration provides a structured pathway for clinical development and potential market entry in the significant heart failure treatment market. However, the company's substantial negative profit margin of -92.3% indicates it is in a capital-intensive development phase, typical for biotechnology firms, requiring significant ongoing investment in R&D and operational infrastructure. The extremely high beta of 7.14 underscores significant market volatility and risk. Future value drivers are contingent on successful clinical trial outcomes for Zofin, regulatory approvals, and the ability to secure additional financing to support its pipeline and commercialization efforts. As an OTC Other-listed company, it faces inherent liquidity and disclosure challenges, necessitating close monitoring of its progress and financial health.

Based on FMP financials and quantitative analysis

BPSR Key Highlights

Gross Margin of 81.6% indicates strong pricing power or efficient cost management for its specialized biological products.

• Profit Margin of -92.3% reflects significant ongoing investment in research and development and operational costs, typical for a biotechnology company in its development phase.
• Beta of 7.14 signifies extremely high volatility, indicating the stock's price movements are significantly more pronounced than the overall market.
• Strategic partnership with Regenerative Care Network focused on exploring Zofin's therapeutic potential for heart failure, a critical pipeline development.
• Specialization in biologically derived cellular and tissue products positions the company within the growing regenerative medicine sector.

Who Are BPSR's Competitors?

BPSR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BPSR's Key Strengths?

High Gross Margin of 81.6% suggests strong product value or cost efficiency in production.

• Specialization in the high-growth regenerative medicine sector with perinatal-derived products.
• Strategic partnership with Regenerative Care Network for the development of Zofin.
• Focused pipeline with a lead candidate (Zofin) targeting a significant medical need (heart failure).

What Are BPSR's Weaknesses?

Significant negative Profit Margin of -92.3% indicates substantial unprofitability and high operational costs.

• Extremely high Beta of 7.14 suggests considerable stock price volatility and market risk.
• Small employee base of 18, which may limit the scope and speed of R&D and commercialization efforts.
• Trading on the OTC market, which typically entails lower liquidity and less stringent disclosure requirements.

What Could Drive BPSR Stock Higher?

BPSR catalyst: Positive clinical trial results for Zofin in heart failure, demonstrating efficacy and safety, could significantly de-risk the product pipeline and attract further investment.

• Achievement of key regulatory milestones, such as successful completion of a clinical trial phase or receipt of an investigational new drug (IND) approval for a new indication.
• Announcement of new strategic partnerships or collaborations that provide additional funding, research capabilities, or commercialization pathways for its product candidates.
• Continued progress in the development and expansion of its perinatal-derived product portfolio, leading to new therapeutic candidates entering preclinical or clinical stages.
• Securing additional financing rounds or grants that provide capital for ongoing research, development, and operational expenses, supporting long-term growth initiatives.

What Are the Key Risks for BPSR?

Significant negative profit margin (-92.3%) indicates substantial unprofitability, raising concerns about long-term financial viability and reliance on external funding.

• Clinical trial failures or unexpected adverse events for Zofin or other pipeline products could halt development, leading to substantial financial losses and reputational damage.
• High stock price volatility (Beta 7.14) and low liquidity on the OTC market expose investors to significant price fluctuations and difficulty in trading shares.
• Challenges in securing adequate future financing to fund ongoing research, development, and potential commercialization efforts, which are capital-intensive for biotech firms.
• Intense competition from larger, more established pharmaceutical and biotechnology companies with greater resources for R&D, clinical trials, and market penetration.

What Are the Growth Opportunities for BPSR?

• Growth opportunity 1: Advancement and Commercialization of Zofin for Heart Failure. The global market for heart failure treatments is substantial and growing, driven by increasing prevalence and an aging population. Successful clinical trials and subsequent regulatory approval for Zofin could unlock a significant revenue stream for Organicell. This opportunity involves navigating complex regulatory pathways and demonstrating superior efficacy or safety profiles compared to existing therapies. The partnership with Regenerative Care Network is crucial for advancing Zofin through these stages, potentially leading to market entry within the next 3-5 years, contingent on trial success and funding.
• Growth opportunity 2: Expansion of Perinatal-Derived Product Portfolio. Organicell specializes in biologically derived cellular and tissue products from perinatal sources. This core technology has broad potential applications beyond heart failure, including areas like orthopedic repair, wound healing, and neurological disorders. Developing and bringing additional perinatal-derived products to clinical trials and eventually to market would diversify the company's pipeline and reduce reliance on a single product. This strategy could involve leveraging existing research platforms and expertise to identify new therapeutic targets over a 5-10 year horizon.
• Growth opportunity 3: Strategic Partnerships and Collaborations. Given the capital-intensive nature of biotechnology and the extensive resources required for clinical development and commercialization, forming additional strategic partnerships is a key growth driver. Collaborations with larger pharmaceutical companies or specialized contract research organizations could provide access to funding, advanced research capabilities, broader distribution networks, and regulatory expertise. Such partnerships could accelerate product development timelines and expand market reach, potentially within the next 2-4 years, by sharing risks and resources.
• Growth opportunity 4: Securing Regulatory Approvals and Market Access. The successful navigation of regulatory approval processes, particularly with the FDA in the United States, is paramount for any biotechnology company. Achieving marketing authorization for Zofin or other pipeline candidates would transition Organicell from a development-stage company to a commercial entity. This involves meticulous clinical data collection, submission of comprehensive dossiers, and adherence to strict manufacturing and quality standards. Expedited pathways or breakthrough designations could shorten timelines, with initial approvals potentially occurring within 3-7 years, depending on trial phases and regulatory interactions.
• Growth opportunity 5: Capitalizing on the Expanding Regenerative Medicine Market. The broader regenerative medicine market is projected for robust growth, driven by scientific advancements, increasing investment, and a growing understanding of regenerative therapies. Organicell's foundational expertise in cellular and tissue products positions it to benefit from this overarching trend. As the market matures and regulatory frameworks become clearer, the demand for innovative biological solutions will likely increase. Expanding research into new indications and staying at the forefront of scientific discovery will allow Organicell to capture a larger share of this market over the long term, potentially over the next 5-10 years.

What Threats Does BPSR Face?

• Failure of clinical trials for Zofin or other pipeline candidates could severely impact future prospects.
• Intense competition from larger pharmaceutical companies and other biotech firms in regenerative medicine.
• Significant capital requirements and potential challenges in securing future financing.
• Regulatory setbacks or delays in product approvals.
• Market perception and liquidity risks associated with trading on the OTC Other tier.

What Are BPSR's Competitive Advantages?

• Specialized expertise in the preparation and handling of biologically derived cellular and tissue products from perinatal sources.
• Potential intellectual property and patents surrounding its lead product candidate, Zofin, and its manufacturing processes.
• Regulatory hurdles and extensive clinical trial requirements create high barriers to entry for new competitors in the regenerative medicine space.
• Established partnership with Regenerative Care Network provides a structured pathway for clinical development and potential market access.
• Proprietary knowledge in isolating, processing, and distributing sensitive biological materials.

What Does BPSR Do?

Organicell Regenerative Medicine, Inc. is a biotechnology enterprise established in 2011 and headquartered in Miami, Florida, with a core specialization in the preparation, distribution, and supply of biologically derived cellular and tissue products across the United States. Initially operating as Biotech Products Services and Research, Inc., the company underwent a strategic rebranding in June 2018 to reflect its evolving focus on regenerative medicine. This transformation positioned Organicell to concentrate on advanced therapeutic solutions. The company's operational model centers on leveraging the potential of perinatal-derived sources for the development of regenerative therapies, aiming to address various medical conditions. A significant current initiative involves a strategic partnership with Regenerative Care Network. This collaboration is specifically dedicated to the comprehensive exploration of Zofin, Organicell's lead product candidate, for its potential therapeutic efficacy in individuals afflicted with heart failure. This partnership underscores Organicell's commitment to advancing its pipeline through clinical investigation and strategic alliances. With a team of 18 employees, Organicell maintains a focused approach on research, development, and the eventual commercialization of its specialized cellular and tissue products, aiming to carve out a distinct niche within the rapidly expanding regenerative medicine landscape. The company's evolution from its founding to its current specialized focus highlights a strategic pivot towards high-potential therapeutic areas within the broader healthcare sector, emphasizing innovation in biological product development and distribution.

What Products and Services Does BPSR Offer?

• Specializes in the preparation of biologically derived cellular products.
• Distributes and supplies tissue products within the United States.
• Focuses on regenerative medicine, utilizing perinatal sources for therapeutic development.
• Engages in research and development of therapies for various medical conditions.
• Maintains a partnership with Regenerative Care Network to explore Zofin's potential for heart failure.
• Aims to develop and commercialize advanced biological solutions for unmet medical needs.

How Does BPSR Make Money?

• Conducts research and development (R&D) to discover and develop novel cellular and tissue products.
• Seeks to obtain regulatory approvals for its product candidates, such as Zofin, to enable commercialization.
• Partners with other entities, like Regenerative Care Network, to advance clinical development and potentially share commercialization efforts.
• Generates revenue through the eventual sale and distribution of its approved biologically derived therapeutic products.
• Focuses on a pipeline approach, investing in multiple product candidates to address various medical conditions.

What Industry Does BPSR Operate In?

Organicell Regenerative Medicine, Inc. operates within the dynamic and rapidly evolving Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by intensive research and development efforts aimed at discovering, developing, and commercializing novel biological products and therapies. Organicell's specific focus on biologically derived cellular and tissue products places it squarely within the regenerative medicine segment, which is experiencing significant growth driven by advancements in cell therapy, gene therapy, and tissue engineering. The global regenerative medicine market is projected to expand substantially, fueled by an aging population, increasing prevalence of chronic diseases, and breakthroughs in biotechnological research. Organicell's competitive landscape includes both established pharmaceutical giants with regenerative medicine divisions and numerous smaller, specialized biotech firms. Its niche in perinatal-derived products offers a specific differentiation, but it must contend with intense competition for intellectual property, clinical trial success, and market share. The company's current efforts with Zofin for heart failure position it to potentially address a large unmet medical need within this competitive environment.

Who Are BPSR's Key Customers?

• Healthcare providers and medical institutions that would administer or prescribe its therapeutic products.
• Research organizations and academic institutions utilizing its specialized biological materials for studies.
• Potentially, patients suffering from conditions like heart failure, who would benefit from its approved therapies.
• Strategic partners who collaborate on product development and commercialization.

The most recent 11 insider filings for Organicell Regenerative Medicine, Inc. break down as 0 sales and 11 purchases. On net that is roughly 65.8M shares acquired (about $6.9M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Organicell Regenerative Medicine, Inc.

Revenue for Organicell Regenerative Medicine, Inc. came in at $2.6M during Q2 2026, a 78.5% improvement versus the preceding quarter. The company recorded a net loss of $145K, with diluted EPS of $-0.02. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, BPSR averaged $-0.15 in diluted EPS.

Return on equity for Organicell Regenerative Medicine, Inc. stands at 455.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -99.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.05 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -18.3%, the inverse of the P/E and a quick read on earnings relative to price.

Company Profile

Organicell Regenerative Medicine, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Miami, US. The company is led by CEO Albert Mitrani. BPSR has traded publicly since 2022.

BPSR Financials

BPSR Latest News

No recent news available for BPSR.

What Investors Ask About Organicell Regenerative Medicine, Inc. (BPSR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources